|
1
|
Rosiñol L, Beksac M, Zamagni E, Van de
Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA,
Dispenzieri A, et al: Expert review on soft-tissue plasmacytomas in
multiple myeloma: Definition, disease assessment and treatment
considerations. Br J Haematol. 194:496–507. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Plasma Cell Disease Group, Chinese Society
of Hematology, Chinese Medical Association; Chinese Myeloma
Committee-Chinese Hematology Association, . Consensus for the
diagnosis and management of extramedullary plasmacytoma in China
(2024). Zhonghua Xue Ye Xue Za Zhi. 45:8–17. 2024.(In Chinese).
PubMed/NCBI
|
|
3
|
Du J: Progress in diagnosis and treatment
of extramedullary plasma cell tumors. J Intern Med Concepts Pract.
15:302–307. 2020.(In Chinese).
|
|
4
|
Touzeau C and Moreau P: How I treat
extramedullary myeloma. Blood. 127:971–976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jagosky MH and Usmani SZ: Extramedullary
disease in multiple myeloma. Curr Hematol Malig Rep. 15:62–71.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He J, Yue X, He D, Zhao Y, Yang Y, Zheng
G, Zhang E, Han X, Wu W, Yang L, et al: Multiple
extramedullary-bone related and/or extramedullary extraosseous are
independent poor prognostic factors in patients with newly
diagnosed multiple myeloma. Front Oncol. 11:6680992021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bladé J, Beksac M, Caers J, Jurczyszyn A,
von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ,
Zamagni E and Richardson P: Extramedullary disease in multiple
myeloma: A systematic literature review. Blood Cancer J. 12:452022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu P, Davies FE, Boyd K, Thomas K, Dines
S, Saso RM, Potter MN, Ethell ME, Shaw BE and Morgan GJ: The impact
of extramedullary disease at presentation on the outcome of
myeloma. Leuk Lymphoma. 50:230–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dingli D, Ailawadhi S, Bergsagel PL, Buadi
FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR,
Kapoor P, et al: Therapy for relapsed multiple myeloma: Guidelines
from the mayo stratification for myeloma and risk-adapted therapy.
Mayo Clin Proc. 92:578–598. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen M, Li X, Zhang JJ, Tang R, Zhan XK,
Fan SB, Zhao FY and Huang ZX: A clinical study on the treatment of
relapsed and refractory multiple myeloma with secondary
extramedullary lesions using a liposome containing doxorubicin
regimen. Chin J Clin Oncol. 49:512–518. 2022.(In Chinese).
|
|
13
|
Gao Y, Huang H, Wang X, Bai B, Huang Y,
Yang H, Zhan Y, Li Y, Li Y, Zhou M, et al: Safety and efficacy of
mitoxantrone hydrochloride liposome in patients with relapsed or
refractory peripheral T-cell lymphoma and extranodal NK/T-cell
lymphoma: A prospective, single-arm, open-label, multi-center,
phase I Clinical trial. Blood. 136 (Suppl 1):36–37. 2020.
View Article : Google Scholar
|
|
14
|
Cai Q, Xia Y, Wang L, Huang H, Wang J, Cai
J and Tian X: Combination of mitoxantrone hydrochloride liposome
with tislelizumab in patients with relapsed or refractory NK/T cell
lymphoma: A phase Ib/I clinical trial. Blood. 142:44702023.
View Article : Google Scholar
|
|
15
|
Mei KC, Liao YP, Jiang J, Chiang M,
Khazaieli M, Liu X, Wang X, Liu Q, Chang CH, Zhang X, et al:
Liposomal delivery of mitoxantrone and a cholesteryl indoximod
prodrug provides effective chemo-immunotherapy in multiple solid
tumors. ACS Nano. 14:13343–13366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jian Y, Liu N, Zhang Y, Gao W, Chen WM,
Zhu HH and Wu Y: Mitoxantrone hydrochloride liposome, bortezomib,
and dexamethasone- based regimen in multiple myeloma patients with
extramedullary plasmacytoma: A pilot study. Blood. 142:66502023.
View Article : Google Scholar
|
|
17
|
Cao HY, Li L, Xue SL and Dai HP:
Chidamide: Targeting epigenetic regulation in the treatment of
hematological malignancy. Hematol Oncol. 41:301–309. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang DY, Cui YS, Liu YZ, Liu LN, Song YP
and Fang BJ: Successful treatment of one case with relapsed
refractory multiple myeloma by chidamide in combination with
bortezomib and dexamethasone. Zhonghua Xue Ye Xue Za Zhi.
37:4632016.(In Chinese). PubMed/NCBI
|
